NAUTILUS BIOTECHNOLOGY INC
NAUTNASDAQTrading Snapshot
- Day Range
- $2.80 β $3.34
- 52-Week Range
- $0.84 β $4.31
- Volume (shares)
- 15,100,307
- Avg Volume (shares)
- β
- Shares Outstanding
- 127.3M
- Next Earnings
- 2027-02-24
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- $234,000
- P/E Ratio
- β
- P/S Ratio
- β
- EPS (TTM)
- $-0.45
- Dividend Yield
- β
- Dilution (1yr)
- +0.4%
NAUTILUS BIOTECHNOLOGY INC
NAUTAbout NAUTILUS BIOTECHNOLOGY INC
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
βLatest News & Updates

Nautilus Biotechnology: Bullish On Voyager's Upcoming Launch
NAUT is extending Voyager from tau into oncology, which I think will give it more applications for its targeted proteoform platform. NAUT also has research collaborations and SEEDS participation. In my view, this corrobo

Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript
Nautilus Biotechnology, Inc. (NAUT) Q3 2026 Earnings Call Transcript

Nautilus Biotechnology Q3 Earnings Call Highlights
Nautilus Biotechnology NASDAQ: NAUT reported third-quarter revenue of $200,000 as it continued its transition toward commercialization of its Voyager proteomics platform, with management reaffirming plans to begin taking

Nautilus to Measure Proteoforms Driving Alzheimer's Disease and Cancer in ARPA-H-Funded SEEDS Consortium
Nautilus expects to receive up to $6 million to bring its Voyagerβ’ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and therapeutics Nautilus exp

Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended Sept

Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or βNautilusβ), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results fo